date,title,source
Oct-17-18,"BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29",GlobeNewswire
Oct-29-18,BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update,GlobeNewswire
Oct-30-18,BCLI: Phase 3 Trial to Be Fully Enrolled by Mid-2019,Zacks Small Cap Research
Nov-07-18,BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences,GlobeNewswire
Nov-21-18,"Detailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Dec-03-18,Do Institutions Own Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shares?,Simply Wall St.
Dec-04-18,BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND,GlobeNewswire
Dec-27-18,BrainStorm Issues 2018 Letter to Shareholders,GlobeNewswire
Jan-03-19,BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week,GlobeNewswire
Jan-07-19,BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis,Zacks Small Cap Research
Jan-25-19,"BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida",GlobeNewswire
Feb-04-19,BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium,GlobeNewswire
Feb-19-19,BrainStorm Issues a Statement to Patients and Shareholders,GlobeNewswire
Feb-21-19,"BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland",GlobeNewswire
Feb-22-19,BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study,GlobeNewswire
Mar-07-19,BrainStorm to Host Business Update Conference Call,GlobeNewswire
Mar-12-19,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",Benzinga
Mar-13-19,Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI),Simply Wall St.
Mar-14-19,BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS,GlobeNewswire
Mar-15-19,BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS,Zacks Small Cap Research
Mar-28-19,Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting,GlobeNewswire
Apr-04-19,BCLI: Two Abstracts to be Presented at AAN Annual Meeting,Zacks Small Cap Research
Apr-30-19,BrainStorms Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases,GlobeNewswire
May-10-19,BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update,GlobeNewswire
May-13-19,BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London,GlobeNewswire
May-21-19,BCLI: Enrollment in Phase 3 ALS Trial to Complete in 3Q19,Zacks Small Cap Research
May-28-19,BrainStorm Senior Management to Present at BIO 2019,GlobeNewswire
May-30-19,BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study,GlobeNewswire
May-31-19,BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting,GlobeNewswire
